Literature DB >> 33230599

Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer.

James R Broughman1, Winston Vuong1, Omar Y Mian2.   

Abstract

OPINION STATEMENT: Although radical cystectomy is considered the gold standard approach for patients with muscle-invasive bladder cancer, tri-modal therapy (TMT) is a well-tolerated and efficacious alternative to radical cystectomy that is underutilized in inoperable patients and rarely offered to cystectomy candidates in the USA. Retrospective data suggest similar outcomes between radical cystectomy and TMT after adjusting for patient selection and other confounding factors. Nearly 70-80% of patients can keep their native bladder with favorable post-treatment quality of life metrics. Current trials are investigating novel combination strategies including immune checkpoint inhibition along with chemoradiation or radiation. Emerging techniques for improved patient selection and risk stratification include incorporating MP-MRI, and novel biomarkers such as inflammatory, stromal, and DNA damage response gene signatures may guide patient selection and expand the landscape of bladder preservation options available to patients in the future.

Entities:  

Keywords:  Bladder cancer; Bladder preservation; Radiation therapy; Urothelial Cancer

Mesh:

Year:  2020        PMID: 33230599      PMCID: PMC7719006          DOI: 10.1007/s11864-020-00800-5

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  29 in total

1.  Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer.

Authors:  C J Stimson; Michael S Cookson; Daniel A Barocas; Peter E Clark; John E Humphrey; Sanjay G Patel; Joseph A Smith; Sam S Chang
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

Review 2.  Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.

Authors:  Kyle J Ericson; Prithvi B Murthy; Darren J Bryk; Rathika R Ramkumar; James R Broughman; Abhinav Khanna; Omar Y Mian; Steven C Campbell
Journal:  Clin Adv Hematol Oncol       Date:  2019-12

3.  A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

Authors:  M Dror Michaelson; Chen Hu; Huong T Pham; Douglas M Dahl; Chin Lee-Wu; Gregory P Swanson; Jacqueline Vuky; R Jeffrey Lee; Luis Souhami; Brian Chang; Asha George; Howard Sandler; William Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-19       Impact factor: 7.038

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

Authors:  Timur Mitin; Daniel Hunt; William U Shipley; Donald S Kaufman; Robert Uzzo; Chin-Lee Wu; Mark K Buyyounouski; Howard Sandler; Anthony L Zietman
Journal:  Lancet Oncol       Date:  2013-07-01       Impact factor: 41.316

6.  Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Authors:  Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart
Journal:  N Engl J Med       Date:  2012-04-19       Impact factor: 91.245

7.  Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.

Authors:  Kimberley S Mak; Angela B Smith; Alec Eidelman; Rebecca Clayman; Andrzej Niemierko; Jed-Sian Cheng; Jonathan Matthews; Michael R Drumm; Matthew E Nielsen; Adam S Feldman; Richard J Lee; Anthony L Zietman; Ronald C Chen; William U Shipley; Matthew I Milowsky; Jason A Efstathiou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-08-24       Impact factor: 7.038

8.  Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Authors:  Sam S Chang; Bernard H Bochner; Roger Chou; Robert Dreicer; Ashish M Kamat; Seth P Lerner; Yair Lotan; Joshua J Meeks; Jeff M Michalski; Todd M Morgan; Diane Z Quale; Jonathan E Rosenberg; Anthony L Zietman; Jeffrey M Holzbeierlein
Journal:  J Urol       Date:  2017-04-26       Impact factor: 7.450

9.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

Review 10.  Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Authors:  Valeria Panebianco; Yoshifumi Narumi; Ersan Altun; Bernard H Bochner; Jason A Efstathiou; Shaista Hafeez; Robert Huddart; Steve Kennish; Seth Lerner; Rodolfo Montironi; Valdair F Muglia; Georg Salomon; Stephen Thomas; Hebert Alberto Vargas; J Alfred Witjes; Mitsuru Takeuchi; Jelle Barentsz; James W F Catto
Journal:  Eur Urol       Date:  2018-05-10       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.